Tag: IL-2R

Elevated peripheral levels of receptor-interacting protein kinase 1 (RIPK1) and IL-8 as biomarkers of human amyotrophic lateral sclerosis

Ethics statement All the animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals and were approved by the Animal Care Committee of Three Gorges University, China (2019060B). The approval of primidone off-label prescription for ALS patients was obtained from the Ethics Committee…

Continue Reading Elevated peripheral levels of receptor-interacting protein kinase 1 (RIPK1) and IL-8 as biomarkers of human amyotrophic lateral sclerosis

Biomarker detects multiple organ involvement at sarcoidosis diagnosis

Blood levels of the angiotensin-converting enzyme (ACE) — a common sarcoidosis biomarker — were able to distinguish between newly diagnosed sarcoidosis patients with single versus multiple organ involvement, a study shows. Also, higher blood levels of interleukin-2 receptor (IL-2R), an inflammatory marker, were linked with multiple organ involvement. ACE and…

Continue Reading Biomarker detects multiple organ involvement at sarcoidosis diagnosis

Anti-IL-2R beta (CD122) Antibody, clone TM-beta1 MSDS – MABF951-100UL

Safety Data Sheet for Anti-IL-2R beta (CD122) Antibody, clone TM-beta1 MABF951-100UL Material Safety Data Sheet or SDS for Anti-IL-2R beta (CD122) Antibody, clone TM-beta1 MABF951-100UL from Merck for download or viewing in the browser. If you are not able to see the SDS please use this link to download it: …

Continue Reading Anti-IL-2R beta (CD122) Antibody, clone TM-beta1 MSDS – MABF951-100UL

31L-APC-100ul | Interleukin 2 Receptor, alpha (IL-2Ra, IL-2R alpha)

Cat# I7663-31L-APC-100ul Size : 100ul Brand : US Biological Host mouse Conjugate APC Isotype IgG1 Clone Number 10B1132 (IL-A111) Grade Affinity Purified Applications IHC IP Shipping Temp Blue Ice Storage Temp 4°C Do Not Freeze Applications: Suitable for use in Immunohistochemistry, Immunoprecipitation and Functional Assays. Other applications not tested. Recommended…

Continue Reading 31L-APC-100ul | Interleukin 2 Receptor, alpha (IL-2Ra, IL-2R alpha)

31L1-100ug | Interleukin 2 Receptor, alpha (IL-2Ra, IL-2R alpha)

Cat# I7663-31L1-100ug Size : 100ug Brand : US Biological Host mouse Conjugate FITC Isotype IgG1 Clone Number 10B1132 (IL-A111) Grade Affinity Purified Applications FC Shipping Temp Blue Ice Storage Temp -20°C The CD25 cell surface antigen is a 55kDa glycoprotein also known as Interleukin-2 receptor alpha chain. Bovine CD25 is…

Continue Reading 31L1-100ug | Interleukin 2 Receptor, alpha (IL-2Ra, IL-2R alpha)

31L-AP-100ul | Interleukin 2 Receptor, alpha (IL-2Ra, IL-2R alpha)

Cat# I7663-31L-AP-100ul Size : 100ul Brand : US Biological Host mouse Conjugate AP Isotype IgG1 Clone Number 10B1132 (IL-A111) Grade Affinity Purified Applications IHC IP Shipping Temp Blue Ice Storage Temp 4°C Do Not Freeze Applications: Suitable for use in Immunohistochemistry, Immunoprecipitation and Functional Assays. Other applications not tested. Recommended…

Continue Reading 31L-AP-100ul | Interleukin 2 Receptor, alpha (IL-2Ra, IL-2R alpha)

Student research celebrated at Health Sciences Research Day

MU School of Medicine students presented roughly 250 research projects at the annual 2023 Health Sciences Research Day (HSRD), held Nov. 10, 2023, and featured the work of undergraduates, medical and nursing students, PhD students and postdoctoral trainees. The research posters covered a variety of topics within the health care…

Continue Reading Student research celebrated at Health Sciences Research Day

New lipidic peptide IK14004 shows promise in treating cancer and reducing autoimmune complications

A recent study published in Nature’s Scientific Reports described a lipidic peptide, named IK14004, which fosters the growth of immunosuppressive T regulatory (Treg) cells and separates interleukin-2 production from interferon-gamma, while also activating CD8+ T cells. Study: An immunomodulating peptide with potential to suppress tumour growth and autoimmunity. Image Credit: crystal light/Shutterstock.com…

Continue Reading New lipidic peptide IK14004 shows promise in treating cancer and reducing autoimmune complications

Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively Four-year follow-up…

Continue Reading Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023

  CRANFORD, N.J., Nov. 9, 2023 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on November 15, 2023….

Continue Reading Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023

Proteomic Analysis Reveals Potential Differences in Patients Achieving VASI 50 Improvements VS Those Who Do Not

A recent study1 involving proteomic analysis found that baseline levels of circulating inflammatory biomarkers of patients with vitiligo may stratify patients who experienced significant repigmentation after treatment with ruxolitinib cream. Furthermore, these differentially-expressed proteins identified potential differences between patients who achieved a Vitiligo Area and Severity Index (VASI) of 50%…

Continue Reading Proteomic Analysis Reveals Potential Differences in Patients Achieving VASI 50 Improvements VS Those Who Do Not

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp. Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated…

Continue Reading Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Data on MDNA113, its

Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific…

Continue Reading Medicenna Presents Preclinical Data on MDNA113, its

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer -November 03, 2023 at 12:00 pm EDT

Medicenna Therapeutics Corp. announced new preclinical data demonstrating proof of concept for the Company?s novel T-MASK (Targeted Metallo/protease Activated SuperKine) platform technology with the Company?s development candidate, MDNA113, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (?SITC?) held in San Diego, CA, from November 1-5, 2023….

Continue Reading Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer -November 03, 2023 at 12:00 pm EDT

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the first quarter ended September 30, 2023. Mesoblast Chief Executive Silviu Itescu said: “During the period we had a very productive meeting with…

Continue Reading Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023

Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion by blocking PD-1 signalling MDNA223 demonstrated superior efficacy and extended survival in multiple immunologically “hot” and “cold” syngeneic tumor models MDNA223 showed synergy with pro-inflammatory agonist (STING)…

Continue Reading Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Recombinant mouse IL-2 Receptor alpha protein (Active) (ab255798)

Recombinant mouse IL-2 Receptor alpha protein (Active) is a HEK 293 Fragment protein 22 to 236 aa range, >90% purity, < 1 EU/µg endotoxin level and validated in SDS-PAGE, FuncS. Alternative names= TAC, p55, p75, CD25, IL2R, p55, p64, CD25, IL2RA, IL2RB, IL2RG, IMD4, IMD41, TCGFR, XSCID, CD122, CD132, IDDM10,…

Continue Reading Recombinant mouse IL-2 Receptor alpha protein (Active) (ab255798)

CD25/IL-2R alpha Antibody (Basiliximab), DyLight 680 – Chimeric, Novus

Applications Western Blot, Flow Cytometry, Immunohistochemistry, Immunofluorescence Clone Basiliximab Dilution Western Blot, Flow Cytometry, Immunohistochemistry, Immunofluorescence Gene Alias CD25, CD25 antigen, IDDM10, IL-2 receptor subunit alpha, IL2R, IL-2R subunit alpha, IL-2-RA, IL2-RA, interleukin 2 receptor, alpha, interleukin-2 receptor subunit alpha, p55, TAC antigen, TCGFR Host Species Human Purification Method Protein…

Continue Reading CD25/IL-2R alpha Antibody (Basiliximab), DyLight 680 – Chimeric, Novus

Immune and cytokine alterations and RNA-sequencing analysis in gestational tissues from pregnant women after recovery from COVID-19 | BMC Infectious Diseases

Baseline characteristics of study participants A total of 40 pregnant women were enrolled into the study, with 13 in the convalescent group and 27 in the control group. During COVID-19 infection in the 13 convalescent women, one had a temporary loss of taste, one had occasional palpitations, and three had…

Continue Reading Immune and cytokine alterations and RNA-sequencing analysis in gestational tissues from pregnant women after recovery from COVID-19 | BMC Infectious Diseases

Genome-Wide Association Study of Alopecia Areata in Taiwan

Introduction Alopecia areata (AA) is one of Taiwan’s most common autoimmune hair diseases and incidence rate of AA is 0.22%.1–3 The main symptoms of AA are rapid, non-scarring hair loss that affects body hair, facial hair, eyelashes, and brows.1,2 In the United States, the prevalence of AA is estimated to…

Continue Reading Genome-Wide Association Study of Alopecia Areata in Taiwan

Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir

CRANFORD, N.J., Sept. 13, 2023 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR) mourns the loss of longtime board member, Howard Safir, who passed away on Monday. Mr. Safir joined the Citius Board of Directors in 2014, providing invaluable counsel to the Citius management team for nearly…

Continue Reading Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir

SACE and IL-2R as serum biomarkers for evaluation of multi-organ involvement and prognosis of sarcoidosis | Respiratory Research

Clinical characteristics Table 1 lists the baseline clinical characteristics of the 832 patients with newly diagnosed pulmonary sarcoidosis from Mar 2013 to Sep 2021 in Shanghai Pulmonary Hospital. Patients included 550 (66.1%) females and 282 (33.9%) males, with a medium age of 52 years (females:54 years, males: 46 years, ranging from…

Continue Reading SACE and IL-2R as serum biomarkers for evaluation of multi-organ involvement and prognosis of sarcoidosis | Respiratory Research

CD25/IL-2R alpha Antibody (186), Alexa Fluor 405 0.1 mL; Alexa Fluor 405:Antibodies,

Antigen CD25/IL-2R alpha Classification Monoclonal Conjugate Alexa Fluor 405 Gene Alias CD25, CD25 antigen, IDDM10, IL-2 receptor subunit alpha, IL2R, IL-2R subunit alpha, IL-2-RA, IL2-RA, interleukin 2 receptor, alpha, interleukin-2 receptor subunit alpha, p55, TAC antigen, TCGFR Immunogen This antibody was obtained from a rabbit immunized with purified, recombinant Mouse…

Continue Reading CD25/IL-2R alpha Antibody (186), Alexa Fluor 405 0.1 mL; Alexa Fluor 405:Antibodies,

EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil

Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J., Sept. 6, 2023 /PRNewswire/ — EOM Pharmaceutical Holdings, Inc (OTC: IMUC) (“EOM”) today announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug…

Continue Reading EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil

Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023

Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023 Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023 CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to…

Continue Reading Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine

Given the therapeutic impact that adoptive TILs transfer has had in the treatment of melanoma with cases of durable responses reported, and the demonstration of tumor-reactive lymphocytes infiltrating OvCa tumors, adoptive TILs transfer has been studied as an immunotherapeutic option for OvCa treatment [14, 36, 37]. In spite of improvements…

Continue Reading Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine

Why measure soluble interleukin-2 receptor levels?

Sponsored Content by TecanAug 22 2023Reviewed by Olivia Frost The measurement of soluble interleukin-2 receptor (sIL-2R) levels in serum or plasma in adults has become a valuable tool for clinicians to assess immune function in vivo as part of the investigation, management, or prognosis of a wide range of diseases….

Continue Reading Why measure soluble interleukin-2 receptor levels?

Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy

Patient characteristics In total, 485 patients were included in the analysis (elevated sIL-2R levels, n = 105; normal sIL-2R levels, n = 380; Supplementary Figure S1 online). The baseline characteristics of the patients at the time of diagnosis in each group are shown in Table 1. The median pre-treatment sIL-2R level value was 707…

Continue Reading Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy

Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles

Soft-randomization of phage-displayed hIL-2 beta chain interface revealed hotspots modulating the interaction Soft-randomization was chosen for an initial mutational scanning at hIL-2/hIL-2R beta interface, focused on solvent-exposed (>20%) hIL-2 residues close to the beta chain (<5 Å). A library of 7 × 107 members was obtained by Kunkel mutagenesis15 with spiked mutagenic oligonucleotides…

Continue Reading Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles

Strategies to therapeutically modulate cytokine action

Cohen, S., Bigazzi, P. E. & Yoshida, T. Commentary. Similarities of T cell function in cell-mediated immunity and antibody production. Cell Immunol. 12, 150–159 (1974). Article  CAS  PubMed  Google Scholar  Keegan, A. D. & Leonard, W. J. in Paul’s Fundamental Immunology 8th edn, ch. 9 (eds Flajnik, M. F., Singh,…

Continue Reading Strategies to therapeutically modulate cytokine action

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

Review doi: 10.1186/s12943-023-01826-7. Affiliations Expand Affiliations 1 Department of Thoracic Surgery, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. 2 Laboratory of Translational Medicine, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese…

Continue Reading Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

Understanding Soluble IL-2R – Nao Medical

Welcome to Nao Medical’s comprehensive guide on Soluble IL-2R! In this blog post, we will delve into the functions, benefits, and applications of Soluble IL-2R in healthcare. Discover how Nao Medical leverages this innovative solution to enhance patient care and outcomes. What is Soluble IL-2R? Soluble IL-2R, also known as…

Continue Reading Understanding Soluble IL-2R – Nao Medical

LOINC 29596-4 CD25 Ag [Presence] in Tissue by Immune stain

es-AR Spanish (Argentina) CD25:concentración arbitraria:punto en el tiempo:tejido, no especificado:ordinal:tinción inmunológica es-ES Spanish (Spain) CD25 Antígeno:PrThr:Punto temporal:Tejido:Ord:Tinción de inmunohistoquímica es-MX Spanish (Mexico) CD25 Ag:Presencia o umbral:Punto temporal:Tejido y frotis:Ordinal:Mancha inmune et-EE Estonian (Estonia) CD25 antigeen:PrThr:Pt:Tis:Ord:ImmuunvärvSynonyms: Järgarvuline Juhuslik Kude fr-CA French (Canada) CD25 , Ag:Présence-Seuil:Temps ponctuel:Tissu:Ordinal:Coloration immunologique fr-FR French (France) CD25…

Continue Reading LOINC 29596-4 CD25 Ag [Presence] in Tissue by Immune stain

Recombinant Human CD25 – IL-2RA (CHO)

Product Type SelectAntibody (536)Biologically Active (52)Capture Antibody (26)Cytokine (6)Detection Antibody (26)Dual ELISpot Set (9)Dual Fluorospot Set (9)ELISA Kit (111)ELISA Set (36)ELISpot Kit (22)ELISpot Pairs (20)ELISpot Set (20)Isotype Control (17)Recombinant Antibody (12)Recombinant Protein (19)SARS-CoV-2 (11)SARSCoV2 (8) Analyte SelectADAM-10 (1)Angiopoietin-2 (3)BCMA (2)BIOTIN (1)c-Myc (1)CD10 (4)CD102 (1)CD102 / ICAM-2 (4)CD105 (5)CD106 (2)CD106 /…

Continue Reading Recombinant Human CD25 – IL-2RA (CHO)

2023-06-20 | NDAQ:CTXR | Press Release

CITI-002 provides a meaningful reduction in symptom severity when compared to individual components alone Dose for Phase 3 trial selected; Citius to schedule end of Phase 2 meeting with the FDA Trial validates Patient Reported Outcome (PRO) instrument developed to support a pivotal Phase 3 study CRANFORD, N.J., June 20,…

Continue Reading 2023-06-20 | NDAQ:CTXR | Press Release

LOINC 14112-7 CD25+CD19+ cells/100 cells in Blood

es-AR Spanish (Argentina) células.CD25+CD19+/100 células:fracción de un número:punto en el tiempo:sangre:cuantitativo: es-ES Spanish (Spain) Células CD25+CD19+/100 células:Fracción numérica:Punto temporal:Sangre:Qn: es-MX Spanish (Mexico) Cells.CD25 + CD19 + / 100 células:Fracción numérica:Punto temporal:Sangre:Cuantitativo: et-EE Estonian (Estonia) Rakud.CD25+CD19+/100 raku kohta:NFr:Pt:B:Qn:Synonyms: Juhuslik Kvantitatiivne Veri fr-CA French (Canada) Cellules.CD25+CD19+/100 cellules:Fraction numérique:Temps ponctuel:Sang:Quantitatif: fr-FR French (France)…

Continue Reading LOINC 14112-7 CD25+CD19+ cells/100 cells in Blood

Solved The diagram represents the results of a flow

Transcribed image text: The diagram represents the results of a flow cytometry experiment in which mouse spleen cells were stained with antibodies directed against different components of the IL-2 receptor (IL-2R). The more antibody that binds to the cells, the further they move along the relevant axis. The number of…

Continue Reading Solved The diagram represents the results of a flow

Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells

Introduction Interleukin (IL)-2 was the first Food and Drug Administration approved immunotherapy for use in patients with metastatic melanoma and renal cell carcinoma.1 2 However, the use of recombinant IL-2 (Proleukin/aldesleukin) has been problematic due to low response rates, off-target effects, and severe dose-dependent toxicities. Due to its potent T-cell…

Continue Reading Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells

CRS Associated With Coagulation Disorders in CAR T-Cell Therapy in Multiple Myeloma

Image Credit: © LASZLO – www.stock.adobe.com A retrospective analysis of patients receiving chimeric antigen receptor (CAR) T-cell therapy identified risk factors and potential indicators for serious coagulopathy related to therapy, according to published findings from the phase 1 LEGEND-2 study (NCT03090659).1 Of 51 patients treated in LEDEND-2, 49% developed coagulation…

Continue Reading CRS Associated With Coagulation Disorders in CAR T-Cell Therapy in Multiple Myeloma

Human CD25 (IL-2R alpha) Recombinant Protein (34-8702-82)

Product Specific Information Description: The human soluble IL-2 receptor alpha chain (sIL-2Ra) is generated by proteolytic cleavage of the cell-surface bound receptor on activated T cells. The IL-2Ra (also known as CD25) is expressed by early progenitors of the T and B lineage, as well as by activated mature T…

Continue Reading Human CD25 (IL-2R alpha) Recombinant Protein (34-8702-82)

NK Cell Therapy Pipeline Insight

PRESS RELEASE Published May 24, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading NK Cell Therapy Pipeline Insight

Citius Pharmaceuticals Advances Mino-Lok Phase 3 Trial Achieving 85 of 92 Events to Date

CRANFORD – Citius Pharmaceuticals, Inc. (‘Citius’ or the ‘Company’) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has advanced its clinical trial for Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections….

Continue Reading Citius Pharmaceuticals Advances Mino-Lok Phase 3 Trial Achieving 85 of 92 Events to Date

NK Cell Therapy Pipeline Booms as 100+ Companies likely to Enter in the Treatment Domain

PRESS RELEASE Published April 18, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading NK Cell Therapy Pipeline Booms as 100+ Companies likely to Enter in the Treatment Domain

TTD | Target: T32240

Target General Infomation Target ID T32240 Former ID TTDC00251 Target Name Interleukin-15 Gene Name IL15 Synonyms IL-15; IL15 Target Type Discontinued Function Cytokine that stimulates the proliferation of T- lymphocytes. Stimulation by IL-15 requires interaction of IL-15 with components of IL-2R, including IL-2R beta and probably IL-2R gamma but not…

Continue Reading TTD | Target: T32240

Ascendis Pharma’s Initial Dose Escalation Results from the Ongoing Phase 1/2 Trial of TransCon IL-2 Accepted for Online Publication at ASCO 2023

COPENHAGEN – Ascendis Pharma A/S (Nasdaq: ASND) today announced that initial dose escalation data from the Company’s ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 alone or in combination with pembrolizumab has been accepted for online publication at ASCO 2023, the annual meeting of the American Society of Clinical Oncology…

Continue Reading Ascendis Pharma’s Initial Dose Escalation Results from the Ongoing Phase 1/2 Trial of TransCon IL-2 Accepted for Online Publication at ASCO 2023

100+ Active Companies working to Develop 185+ Pipeline Therapies for NK Cell Therapy Treatment

PRESS RELEASE Published March 23, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading 100+ Active Companies working to Develop 185+ Pipeline Therapies for NK Cell Therapy Treatment

ADC Therapeutics : Annual Report – Form 6-K

ADC Therapeutics SA 2022 Annual Report Table of Contents Letter to Shareholders Business Update Financial Review Corporate Governance Report from the Auditor on the Consolidated IFRS Financial Statements Consolidated IFRS Financial Statements for the Year Ended December 31, 2022 Report from the Auditor on the Statutory Financial Statements of ADC…

Continue Reading ADC Therapeutics : Annual Report – Form 6-K

Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank

CRANFORD, N.J., March 13, 2023 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. About Citius Pharmaceuticals, Inc. Citius is a late-stage…

Continue Reading Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank

Roswell Park Researchers Present New Approach to Understanding Challenging CAR T-Cell Toxicities

HIGHLIGHTS Preclinical model looked at cytokine release syndrome, neutropenia Experts call work a “major advancement” in understanding these toxicities Poised to help improve quality of life in patients treated with CAR-T therapy During the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13 in New Orleans,…

Continue Reading Roswell Park Researchers Present New Approach to Understanding Challenging CAR T-Cell Toxicities

NK Cell Therapy Pipeline Analysis Demonstrates Novel 100+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

PRESS RELEASE Published February 21, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading NK Cell Therapy Pipeline Analysis Demonstrates Novel 100+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be

Collaboration with the laboratory of Dr. Michael Dustin elucidates the mechanism of action of Immuno-STATs in activating disease-specific T cells by mimicking the natural formation of immune synapses BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics…

Continue Reading Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be

Question #6 A 31-year-old man comes to the physician for evaluation of chronic cough, sinus pain, and nasal discharge.He has a history of frequent upper respiratory infections and recurrent sinusitis since childhood. He is also concerned about fertility,as he and his wife have been trying to conceive for 5 years unsuccessfully.Pulmonary examination shows crackles and wheezing throughout both lung fields.A CT scan of the chest is shown.The most likely cause of this patient’s condition is a defect in which of the following molecular structures? 10.00mm/dn Answer Image A IL-12 receptor B IL-2R gamma chain c NADPHoxidase

We don’t have your requested question, but here is a suggested video that might help. Best Match Question: Chief Complaint: 68-year-old man with a cough and dyspnea for the past week. History: Daniel McDonald, a 68-year-old white male with a history of smoking suffered from chronic bronchitis for which…

Continue Reading Question #6 A 31-year-old man comes to the physician for evaluation of chronic cough, sinus pain, and nasal discharge.He has a history of frequent upper respiratory infections and recurrent sinusitis since childhood. He is also concerned about fertility,as he and his wife have been trying to conceive for 5 years unsuccessfully.Pulmonary examination shows crackles and wheezing throughout both lung fields.A CT scan of the chest is shown.The most likely cause of this patient’s condition is a defect in which of the following molecular structures? 10.00mm/dn Answer Image A IL-12 receptor B IL-2R gamma chain c NADPHoxidase

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update

$36.9 million in cash and cash equivalents as of December 31, 2022; runway through February 2024 Uptick in patient recruitment for Mino-Lok® Phase 3 trial Halo-Lido Phase 2b trial nearing completion CRANFORD, N.J., Feb. 10, 2023 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (NASDAQ: CTXR), a late-stage biopharmaceutical…

Continue Reading Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update

Differential Role Of Il-2r Signaling For Cd8(+) T Cell Responses In Acute And Chronic Viral Infections

IL-2 is a cytokine with multiple and even divergent functions; it has been described as a key cytokine for in vitro T cell proliferation but is also essential for down-regulating T cell responses by inducing activation-induced cell death as well as regulatory T cells. The in vivo analysis of…

Continue Reading Differential Role Of Il-2r Signaling For Cd8(+) T Cell Responses In Acute And Chronic Viral Infections

Short Communication Developmental Expression Of Il-2-Receptor Light Chain (Cd25) In The Chicken Embryo

Thymocyte differentiation obeys the same fundamental principles in mammals as in avian species. This parallelism does not only affect the developmentally controlled acquisition of CD3, 4, 8, and TcR isotype expression, but also concerns CD25, the light chain of the interleukin-2 receptor (IL-2R). On chicken thymocytes, surface CD25, which…

Continue Reading Short Communication Developmental Expression Of Il-2-Receptor Light Chain (Cd25) In The Chicken Embryo

BOMIPROT

1 Bomi8228 Probetacellulin Q9TTC5 2 Bomi5121 Dimethylaniline monooxygenase [N-oxide-forming] 3/Dimethylaniline oxidase 3/Hepatic flavin-containing monooxygenase 3/Trimethylamine monooxygenase Q8HYJ9 3 Bomi10437 Uterine milk protein P46201 4 Bomi9179 Signal transducer and activator of transcription 5A/Mammary gland factor Q95115 5 Bomi9003 Selenoprotein P P49907 6 Bomi3613 Acetyl-CoA carboxylase 1 Q9TTS3 7 Bomi5003 Cytoskeleton-associated protein…

Continue Reading BOMIPROT

Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID (Q28241595): Preview

Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID (Q28241595) scientific article (publication date: 11 November 1994) Language: Englishfrançais (French)español (Spanish)Deutsch (German)dansk (Danish)Nederlands (Dutch)汉语 (Chinese)العربية (Arabic)italiano (Italian)latviešu valoda (Latvian)eesti keel (Estonian)suomi (Finnish)português (Portuguese)svenska (Swedish)Norsk (Norwegian)日本語 (Japanese)हिन्दी (Hindi)Lëtzebuergesch (Luxembourgish) Read more here: Source…

Continue Reading Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID (Q28241595): Preview

il15 related Antibodies, Proteins, cDNA and ELISA Kits- Cusabio

Interleukin-15 is a protein in humans that is encoded by IL15 gene. Cytokine that stimulates the proliferation of T-lymphocytes. Stimulation by IL-15 requires interaction of IL-15 with components of IL-2R, including IL-2R beta and probably IL-2R gamma but not IL-2R alpha. il15 Proteins il15 Proteins for Mus musculus (Mouse) il15…

Continue Reading il15 related Antibodies, Proteins, cDNA and ELISA Kits- Cusabio

COVID-19 vaccines in liver transplant recipients

Introduction Three waves of world wild emerging severe infectious disease pandemics have been presented during this century because of the coronavirus. The severe acute respiratory syndrome (SARS) outbreak in southern China since 2002 has spread to 8096 cases from 29 countries, with a mortality of 9.6%.1 Middle East respiratory syndrome…

Continue Reading COVID-19 vaccines in liver transplant recipients

Soluble IL-2R Levels at Baseline Predict the Development of Severe Respiratory Failure and Mortality in COVID-19 Patients

This article was originally published here Viruses. 2022 Apr 10;14(4):787. doi: 10.3390/v14040787. ABSTRACT Risk stratification of coronavirus disease-19 (COVID-19) patients by simple markers is critical to guide treatment. We studied the predictive value of soluble interleukin-2 receptor (sIL-2R) for the early identification of patients at risk of developing severe clinical…

Continue Reading Soluble IL-2R Levels at Baseline Predict the Development of Severe Respiratory Failure and Mortality in COVID-19 Patients

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

Anaveon – ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rβγ selectivity – – A Phase II program of ANV419 has been initiated in multiple tumor types, including melanoma, alongside multiple combination trials – BASEL, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) — Anaveon, a…

Continue Reading Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

Can depression, anxiety and stress be treated with physical exercise?

“Over the past few years, with the pandemic, our anxious amygdala, the part of the brain that recognizes danger and puts us on high alert, has been on hyperalert, triggering a near-constant stress response” (Dmitry Kostyukov/The New York Times ) When Jennifer Heisz She was in grad school, borrowed a…

Continue Reading Can depression, anxiety and stress be treated with physical exercise?

Recombinant Cynomolgus CD25/IL-2R alpha His-tag Protein, CF (10716-RL)

References Minami, Y. et al. (1993) Annu. Rev. Immunol. 11:245. Kovanen, P.E. and Leonard, W.J. (2004) Immunol. Rev. 202:67. Bluestone, J.A. and Tang, Q. (2005) Curr. Opin. Immunol. 17:638. Hatakeyama, M. et al. (1989) Science 244:551. Takeshita, T. et al. (1992) Science 257:379. Stauber, D. et al. (2006) Proc. Natl….

Continue Reading Recombinant Cynomolgus CD25/IL-2R alpha His-tag Protein, CF (10716-RL)

A cross-sectional healthy-control study of serum inflammatory biomarkers interleukin (IL)-1B and IL-2R in panic disorder patients and their offspring

Available online 11 March 2022 doi.org/10.1016/j.jpsychires.2022.03.004Get rights and content Highlights • Alterations in the immune system have been associated with a variety of mental illnesses. • An increase in circulating inflammatory cytokines is observed not only in people with mental disorders but also in their first-degree relatives. • Panic disorder…

Continue Reading A cross-sectional healthy-control study of serum inflammatory biomarkers interleukin (IL)-1B and IL-2R in panic disorder patients and their offspring

Rat Anti-Mouse CD25/IL-2R Antibody

Name Rat Anti-Mouse CD25/IL-2R Antibody (GWB-31929F) Related Product Names Rat Anti-Mouse CD25/IL-2Ra-PE; PMP-22; Protein CD25; SR13 myelin protein; Schwann cell membrane glycoprotein; SAG Cd25; Pmp-22Rat Anti-Mouse CD25/IL-2RPmp22 Gene Symbol IL2RA Gene Fullname Interleukin-2 receptor subunit alpha Gene id 3559 Swissprot ID P01589 Protein Name Interleukin-2 receptor subunit alpha Protein Accession…

Continue Reading Rat Anti-Mouse CD25/IL-2R Antibody

Anti- Interleukin 2 Receptor, alpha (IL-2Ra, IL-2R alpha, CD25, IDDM10, Ly43, p55, T Cell Growth … by USBiological, Cat. No. I7663-31Q1-HRP-100uL

* CHF, excl. 7.7% VAT and shipping costs You are currently not logged in. Please register to see prices including your discount. Registration may take up to 24h. For guest orders the standard discount of your institution will apply and discounts are visible on the order confirmation. Product Description Anti-…

Continue Reading Anti- Interleukin 2 Receptor, alpha (IL-2Ra, IL-2R alpha, CD25, IDDM10, Ly43, p55, T Cell Growth … by USBiological, Cat. No. I7663-31Q1-HRP-100uL

SUPPRESSION OF DIALYSIS PATIENTS’ LYMPHOCYTE IL-2R EXPRESSION BY GLUCOCORTICOIDS AND CYCLOSPORINE

Previous studies have shown interindividual heterogeneity in the suppressive effects of glucocorticoids and cyclosporine (CsA) on the proliferation responses of dialysis patients’ peripheral blood mononuclear cells (PBMC). In addition, methylprednisolone (MP) was shown to be significantly more suppressive than prednisolone (P), and PBMC from patients on peritoneal dialysis (PD) were…

Continue Reading SUPPRESSION OF DIALYSIS PATIENTS’ LYMPHOCYTE IL-2R EXPRESSION BY GLUCOCORTICOIDS AND CYCLOSPORINE

Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences

H.C. Wainwright BioConnect 2022 Conference January 10-13, 2022 Biotech Showcase Virtual Conference January 17-19, 2022 CRANFORD, N.J., Jan. 4, 2022 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on…

Continue Reading Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences

Toll-like receptor 2/4 in Chinese patients with sepsis

Introduction Sepsis is a life-threatening organ dysfunction that results from an exaggerated host immune response to disseminate infection.1 Despite improvements in treatment strategies, sepsis remains a leading cause of death in critically ill patients worldwide.2 Low platelet number, known as thrombocytopenia, is common in infectious diseases (also sometimes referred to…

Continue Reading Toll-like receptor 2/4 in Chinese patients with sepsis

IL-2R binders queued for testing

Starting in summer 2021, we ran 6 rounds of IL-2R binder design puzzles. Now we’ve selected 115 promising Foldit designs to test for binding in the lab! In early 2022, we will conduct a FACS experiment to test if these protein designs successfully bind to the IL-2R target. Targeting IL-2R…

Continue Reading IL-2R binders queued for testing

rosetta fold vs alphafold 2

S. Both AlphaFold and Xu use simple folding engines L-BFGS (L- Broyden–Fletcher–Goldfarb– Shanno (BFGS)) and CNS (Crystallography and NMR System), respectively, i.e., improvements come from a better energy potential using distributional information. The phase problem is a problem, to the point that in the past decade, several structures, such as M-PMV…

Continue Reading rosetta fold vs alphafold 2